Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction

Cancer

Volumn 100, Issue 11, 2004, Pages 2347-2354

  Ajani, Jaffer A ^a   Walsh, Garrett ^a   Komaki, Ritsuko ^a   Morris, Jeff ^a   Swisher, Stephen G ^a   Putnam Jr , Joe B ^a   Lynch, Patrick M ^a   Wu, Tsung Teh ^a   Smythe, Roy ^a   Vaporciyan, Ara ^a   Faust, Josephine ^a   Cohen, Deborah S ^a   Nivers, Rebecca ^a   Roth, Jack A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiotherapy; Chemotherapy; Esophagus; Gastroesophageal junction; Locoregional carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL; IRINOTECAN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; ENDOSCOPIC ECHOGRAPHY; ESOPHAGITIS; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; MYALGIA; NAUSEA; NEUROPATHY; PREOPERATIVE CARE; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ENDOSONOGRAPHY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PREOPERATIVE CARE; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 2442705655     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20284     Document Type: Article

References (18)

1. American Cancer Society. Esophageal cancer. Available from URL: http://www.cancer.org/downloads/PRO/ EsophagealCancer.pdf [accessed April 21, 2004].
2. American Cancer Society. Estimated new cancer cases and deaths, by sex, US 2003. Available from URL: http: www. cancer.org/downloads/STT/CAFF2003PWsecured.pdf [accessed April 21, 2004].
3. Coia LR, Minsky BD, Berkey BA, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. J Clin Oncol. 2000;18:455-462.
4. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1997;335:462-467.
5. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med. 1997;337:161-167.
6. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with local-regional esophageal carcinoma. J Clin Oncol. 2001;15:305-313.
7. Ilson DH. Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999;17:3270-3275.
8. Ajani JA, Baker J, Pisters PW, et al. CPT-II plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002;94:641-656.
9. Komaki R, Janjan NA, Ajani NA, et al. Phase I study of irinotecan and concurrent radiation therapy for upper G1 tumors. Oncology (Huntingt). 2000;14(Suppl. 14):34-37.
10. Ilson DH, Bains M, Kelsen DP, et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol. 2003;21:2926-2933.
11. Ajani JA, Komaki R, Putnam JB, et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus of gastroesophageal junction. Cancer. 2001;92:279-286.
12. Schnirer II, Komaki R, Yao JC, et al. A pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001;24:91-95.
13. Siwert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457-1459.
14. Gibson MK, Forastiere AA. Combined-modality therapy for esophageal cancer: are we making progress? Cancer J. 2003;9:238-239.
15. Ketsen DP, Ginsberg R, Pajak T, et al. Preoperative chemotherapy followed by operation versus operation alone for patients with localized esophageal cancers: a US national intergroup study. N Engl J Med. 1998;339:1979-1984.
16. Swisher S, Ajani J, Komaki R, et al. A CPT-II-Taxotere-5-FU regimen for induction and concurrent chemoradiotherapy prior to surgery in patients with resectable esophageal or gastroesophageal carcinoma. Proc Am Soc Clin Oncol. 2003;22:272.
17. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428-432.
18. Swisher SG, Erasmus J, Maish M, et al. PET predicts pathologic response and long-term Survival following preoperative chemoradiotherapy in esophageal cancer. ASCO virtual meeting. 2004 Gastrointestinal cancers symposium. Available from URL: http://www.asco.org/ac/1,1003-12-00251100_18-0027-00_19-00253,00.asp [accessed April 21, 2004].